Where now for anti-EGF receptor therapies in colorectal cancer?

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1543-1553

  Shaw, Paul H S ^a   Adams, Richard A ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

biomarkers; cetuximab; colorectal cancer; EGFR; monoclonal antibody; panitumumab

Indexed keywords

AMPHIREGULIN; B RAF KINASE; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; GANITUMAB; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN PIK3CA; PROTEIN TYROSINE KINASE; RILOTUMUMAB; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER RESISTANCE; COLORECTAL CANCER; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 80054724227     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.143     Document Type: Review

References (104)

1. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis. Colon Rectum 40(1), 15-24 (1997). (Pubitemid 27056393)
2. Sargent DJ, Conley BA, Allegra C et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23(9), 2020-2027 (2005). (Pubitemid 46211382)
3. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004). (Pubitemid 41079832)
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004). (Pubitemid 38944402)
5. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353(16), 1652-1654 (2005). (Pubitemid 41464703)
6. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005). (Pubitemid 46211358)
7. Etienne-Grimaldi MC, Cayre A, Penault-Llorca F et al. EGFR expression in colon cancer: a break in the clouds. Ann. Oncol. 17(12), 1850-1851 (2006). (Pubitemid 44884064)
8. Francoual M, Etienne-Grimaldi MC, Formento JL et al. EGFR in colorectal cancer: more than a simple receptor. Ann. Oncol. 17(6), 962-967 (2006). (Pubitemid 43778987)
9. Adams RA, Smith CS, Wilson RH et al; on behalf of the MRC COIN Trial Investigators. Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): the MRC COIN trial experience. ASCO 2011 Gastrointestinal Cancers Symposium 2011: J. Clin. Oncol. 29(Suppl. 4) (2011) (Abstract 359).
10. Barber TD, Vogelstein B, Kinzler KW et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351(27), 2883 (2004). (Pubitemid 40051921)
11. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279-286 (2005). (Pubitemid 40590264)
12. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fuoropyrimidines. J. Clin. Oncol. 24(30), 4914-4921 (2006). (Pubitemid 46630920)
13. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101(19), 1308-1324 (2009).
14. Shia J, Klimstra DS, Li AR et al. Epidermal growth factor receptor expression and gene amplifcation in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod. Pathol. 18(10), 1350-1356 (2005). (Pubitemid 41348654)
15. Spindler KL, Lindebjerg J, Nielsen JN et al. Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int. J. Oncol. 29(5), 1159-1165 (2006).
16. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007). (Pubitemid 47325606)
17. Jacobs B, De Roock W, Piessevaux H et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 27(30), 5068-5074 (2009).
18. Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a Phase I dose-escalation study. J. Clin. Oncol. 28(7), 1181-1189 (2011).
19. Baker JB, Dutta D, Watson D et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br. J. Cancer 104, 488-495 (2011).
20. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fuoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311-2319 (2008).
21. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
22. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007). (Pubitemid 350106711)
23. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007). (Pubitemid 46797944)
24. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
25. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab effcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
26. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
27. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the frst-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
28. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fuorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as frst-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
29. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fuorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706-4713 (2010).
30. Seymour MT. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 3523).
31. Kohne CH, Rougier, P, Stroh C et al. Cetuximab with chemotherapy (CT) as frst-line treatment for metastatic colorectal cancer (mCRC), a meta-analysis of the CRYSTAL and OPUS studies according to K-RAS and BRAF mutation status. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 21-22 January 2011.
32. Maughan TS, Adams RA, Smith CS et al. Identifcation of potentially responsive subsets when cetuximab is added to oxaliplatin-fuoropyrimidine chemotherapy (CT) in frst-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J. Clin. Oncol. 28(Suppl. 15s) (2010) (Abstract 3502).
33. Adams RA, Meade AM, Madi A et al. Toxicity associated with combination oxaliplatin plus fuoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br. J. Cancer 100(2), 251-258 (2009).
34. Ochenduszko SL, Krzemieniecki K. Targeted therapy in advanced colorectal cancer: more data, more questions. Anticancer Drugs 21(8), 737-748 (2010).
35. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based frst-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet 377(9783), 2103-2114 (2011).
36. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812-1820 (2010).
37. Tejpar S, Bokemeyer C, Celik I et al. Infuence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with frst-line chemotherapy with or without cetuximab. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 3511).
38. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the effcacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753-762 (2010).
39. Di Nicolantonio F, Martini M, Molinari F A et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008).
40. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69(5), 1851-1857 (2009).
41. Di Nicolantonio F, Sartore-Bianchi A, Molinari F et al. BRAF, PIK3CA and KRAS mutations and loss of PTEN expression impair response to EGFR targeted therapies in metastatic colorectal cancer. Am. Assoc. Cancer Res. 68, 1953 (2009).
42. Yokota T, Ura T, Shibata D et al. Evaluation of BRAF mutation as a powerful prognostic factor in advanced and recurrent colorectal cancer. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 21-22 January 2011.
43. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fuorouracil, and leucovorin as frst-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
44. Tejpar S, Popovici V, Delorenzi M et al. Mutant KRAS and BRAF gene expression profles in colorectal cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J. Clin. Oncol. 28(15 Suppl.) (2010) (Abstract 3505).
45. Keyse SM. Dual-specifcity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27(2), 253-261 (2008).
46. De Roock SF, Biesmans B, Jacobs B et al. DUSP expression as a predictor of outcome after cetuximab treatment in Kras wild type and mutant colorectal tumors. Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 17-19 January 2009.
47. Souglakos J, Philips J, Wang R et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101(3), 465-472 (2009).
48. Sangale Z, Prass C, Carlson A et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl. Immunohistochem. Mol. Morphol. 19(2), 173-183 (2010).
49. Russo A, Bazan V, Iacopetta B et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive signifcance of p53 mutation: infuence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23(30), 7518-7528 (2005). (Pubitemid 46291815)
50. Di Fiore F, Blanchard F, Oden-Gangloff A et al. TP53 mutations in irinotecan-refractory KRAS wt-BRAF wt metastatic colorectal cancer patients treated with cetuximab-based chemotherapy. J. Clin. Oncol. 29(Suppl. 4) (2011) (Abstract 426).
51. Shaw P. Anti Epidermal Growth Factor Therapy Modelled in The Mouse. Cardiff University, Cardiff, Wales, UK (2010).
52. Saif M W, Kaley K, Chu E et al. Safety and effcacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin. Colorectal Cancer 5(5), 315-318 (2008).
53. Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab. Ivest. J. Tech. Methods Pathol. 86(10), 981-986 (2006). (Pubitemid 44423063)
54. Paule B, Castagne V, Picard V et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med. Oncol. 27(4), 1066-1072 (2011).
55. Wheeler DL, Huang S, Kruser TJ et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27(28), 3944-3956 (2008). (Pubitemid 351913636)
56. Shankaran H, Wiley HS, Resat H. Receptor downregulation and desensitization enhance the information processing ability of signalling receptors. BMC Syst. Biol. 1, 48 (2007).
57. Hyun TS, Rao DS, Saint-Dic D et al. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. J. Biol. Chem. 279(14), 14294-14306 (2004). (Pubitemid 38468970)
58. Hyun TS, Ross TS. HIP1: traffcking roles and regulation of tumorigenesis. Trends Mol. Med. 10(4), 194-199 (2004). (Pubitemid 38410978)
59. Nevo J, Mattila E, Pellinen T et al. Mammary-derived growth inhibitor alters traffc of EGFR and induces a novel form of cetuximab resistance. Clin. Cancer Res. 15(21), 6570-6581 (2009).
60. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12(17), 5064-5073 (2006). (Pubitemid 44453332)
61. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Rev. 9(7), 463-475 (2009).
62. Lee D, Yu M, Lee E et al. Tumor-specifc apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J. Clin. Invest. 119(9), 2702-2713 (2009).
63. Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126), 437-441 (2007). (Pubitemid 46160912)
64. Scartozzi M, Mandolesi A, Giampieri R et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 16(1), 53-60 (2011).
65. Kountourakis P, Pavlakis K, Psyrri A et al. Prognostic signifcance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6, 46 (2006).
66. Valabrega G, Montemurro F, Sarotto I et al. TGFa expression impairs trastuzumab-induced HER2 downregulation. Oncogene 24(18), 3002-3010 (2005). (Pubitemid 40675531)
67. Li C, Iida M, Dunn EF, Ghia AJ et al. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28(43), 3801-3813 (2009).
68. Shanmugam C, Jhala NC, Katkoori VR et al. Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer 116(15), 3577-3586 (2010).
69. Price-Schiavi SA, Jepson S, Li P et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 99(6), 783-791 (2002). (Pubitemid 34575694)
70. Weber MM, Fottner C, Liu SB et al. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95(10), 2086-2095 (2002). (Pubitemid 35253369)
71. Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 68(20), 8322-8332 (2008).
72. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118(7), 2609-2619 (2008). (Pubitemid 351949788)
73. Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J. Natl Cancer Inst. 93(24), 1852-1857 (2001). (Pubitemid 34048651)
74. Dallas NA, Xia L, Fan F et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69(5), 1951-1957 (2009).
75. Levy EM, Sycz G, Arriaga JM et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immunity 15(2), 91-100 (2009).
76. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 16(9), 2489-2495 (2011).
77. Geva R. An international consortium study in chemorefractory metastatic colorectal cancer patients to assess the impact of FCGR polymorphisms on cetuximab effcacy. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 3528).
78. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the effcacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 118(11), 3574-3581 (2008).
79. Meng J, Peng H, Dai B et al. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol. Ther. 8(21), 2073-2080 (2009).
80. Rodriguez-Viciana P, Warne PH, Dhand R et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370(6490), 527-532 (1994). (Pubitemid 24264918)
81. Kim SM, Kim JS, Kim JH et al. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to geftinib in HCC827 NSCLC cells. Cancer Lett. 296(2), 150-159 (2010).
82. Zuo Q, Shi M, Chen J et al. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. Biomed. Pharmacother. 65(3), 168-174 (2011).
83. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006). (Pubitemid 46021510)
84. Frank DJ, Brooks W, Kim et al. A Phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma. J. Clin. Oncol. 28(Suppl.) (2010) (Abstract e14092).
85. Haluska P, Carboni JM, TenEyck C et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7(9), 2589-2598 (2008).
86. Huang F, Greer A, Hurlburt W et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69(1), 161-170 (2009).
87. Kaulfuss S, Burfeind P, Gaedcke J et al. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol. Cancer Ther. 8(4), 821-833 (2009).
88. Reidy DL, Vakiani E, Fakih MG et al. Randomized, Phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 28(27), 4240-4246 (2011).
89. Eng C. A randomized, Phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): primary and biomarker analyses. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 3500).
90. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61(13), 5090-5101 (2001). (Pubitemid 32681540)
91. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 10(2), 784-793 (2004). (Pubitemid 38174017)
92. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
93. Punt C, Tol,J, Rodenburg, CJ et al. Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract LBA4011).
94. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
95. Grothey A. EGFR antibodies in colorectal cancer: where do they belong? J. Clin. Oncol. 28(31), 4668-4670 (2010).
96. Sharma M, Kozloff M. Modi SS et al. Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: a Phase II trial of the University of Chicago Phase II consortium. Presented at: Gastrointestinal Cancers Symposium. CA, USA, 21-22 January 2011.
97. Lieu CH, Wolff RA, Eng C et al. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 28(Suppl. 15) (2010) (Abstract 3536).
98. Strickler J. Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. J. Clin. Oncol. 29(Suppl. 4) (2011) (Abstract 513).
99. She QB, Halilovic E, Ye Q et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18(1), 39-51 (2011).
100. Chandarlapaty S, Sawai A, Scaltriti M et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19(1), 58-71 (2011).
101. Serra V, Scaltriti M, Prudkin L et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30(22), 2547-2557 (2011).
102. Oliveira S, Schiffelers RM, van der Veeken J et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J. Control Release 145(2), 165-175 (2011).
103. Cragg MS, Harris C, Strasser A et al. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. 9(5), 321-326 (2009).
104. Cragg MS, Kuroda J, Puthalakath H et al. Geftinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4(10), 1681-1689; discussion 1690 (2007).